Catalyst
Slingshot members are tracking this event:
Bristol-Myers Squibb (BMY) Fails Phase 2 EkkiKIR Trial Evaluating Innate Pharma's (IPHYF) Lirilumab in Treatment of Acute Myeloid Leukemia (AML)
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 06, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 2, Ekkikir, Lirilumab, Acute Myeloid Leukemia
